US News

First patient set to receive controversial Biogen Alzheimer’s drug

Published by

By Deena Beasley (Reuters) – A U.S. hospital on Wednesday will give the first infusion of an expensive, controversial new Alzheimer’s drug from Biogen Inc before Medicare had even said what it will pay for – and with some doctors upset by its approval last week. The first administration of the drug, Aduhelm, outside of a clinical trial is scheduled to take place in Providence, Rhode Island, at Butler Hospital’s Memory and Aging Program. “We are opening a new era in treatment,” Brown University Medical School neurology professor Dr. Stephen Salloway told Reuters. He said the Butler Hospital pro…

Read More

Facebook Comments

Check Also

Mass Shootings On Course For Record Year As US Transforms Into Violent Mess

Mass Shootings On Course For Record Year As ...